Skip to main content
Communications Biology logoLink to Communications Biology
. 2025 May 8;8:657. doi: 10.1038/s42003-025-08063-2

Determination and validation of design space for mesenchymal stem cell cultivation processes using prediction intervals

Keita Hirono 1, Yusuke Hayashi 1, Isuru A Udugama 1, Mohamed Rami Gaddem 1, Kenjiro Tanaka 2, Yuto Takemoto 2, Ryuji Kato 2,3, Masahiro Kino-oka 4, Hirokazu Sugiyama 1,
PMCID: PMC12062477  PMID: 40341300

Abstract

In regenerative medicine, mesenchymal stem cells (MSCs) constitute a promising therapeutic route for many diseases. The current quality-by-design guidelines do not clearly define a framework for MSC production. Here, we suggest and experimentally validate a model-based method to determine design spaces (DSs) for MSC cultivation. A kinetic model used in previous work was employed; part of the experimental data was used to re-estimate the maximum specific growth rate in the kinetic model and then calculate the prediction intervals of this parameter. Subsequently, regions of seeding density and harvesting time where both the upper and lower limits of growth predictions met the acceptable number of cells and confluency with given risk levels were defined as DSs. Finally, the established DS was validated with the remaining data; it allowed better predictions of the cell numbers and confluency under specific cultivation conditions and improved the overall robustness of MSC cultivation processes.

graphic file with name 42003_2025_8063_Figa_HTML.jpg

Subject terms: Computational models, Stem-cell biotechnology


This work developed a method to determine and experimentally validate design spaces for mesenchymal stem cell cultivation using mathematical modeling and simulation.

Introduction

Mesenchymal stem cells (MSCs) are promising for cell therapy applications because of their many therapeutic functions. MSC products have received regulatory approval, and many preclinical/clinical studies on autologous and allogeneic cells1 to treat various conditions, such as traumatic spinal cord injury2, graft-versus-host disease3, and neurological treatments4, are ongoing. The demand for high-quality MSCs for potential clinical applications in cell therapy is increasing. For example, there are 2.8 × 105 new cases of Crohn’s disease per year worldwide5,6, typically requiring adult single doses of 1.2 × 108 MSCs7, suggesting a total demand of >3.0 × 1013 MSCs per year for this disease alone. The number of MSCs can be increased through cultivation processes to satisfy cell demands, especially for patient-specific therapy6.

The quality of cells in cultivation processes is a critical aspect in terms of phenotypic and functional characteristics of MSCs6. In general, for MSCs, cell phenotype is assessed by cell surface biomarker analysis8 with the minimum identity criteria9, while cell potency is demonstrated by functional assays10 regarding immunomodulation11, differentiation12, and secretion of paracrine factors13 as well as self-renewal14. Moreover, confluency caused by too many adhesion cells (a high cell density) in a cultivation space, which can decrease cell growth ability15, can be a quality attribute of interest. Additionally, cell aging is associated with the accumulation of cell divisions through long-term cultivation, which can decrease the differentiation potential16 and be a critical reflector of MSC quality. One major challenge in ensuring the quality of MSCs is accounting for the intrinsic heterogeneity of cells, such as growth dynamics depending on donors or starting cells, toward efficient and reliable cultivation conditions.

Thepharmaceutical industry has addressed the need to satisfy both the anticipated demand growth of MSCs and comply with international regulations6. Here, quality by design (QbD)17 is a systematic approach to facilitate pharmaceutical development and ensure product quality. Specifically, the concept of a design space (DS)17, namely, a multidimensional combination of critical process parameters (CPPs) and critical material attributes (CMAs) to ensure critical quality attributes (CQAs), can be applied to MSC cultivation processes6. For example, a DS was shown with two CPPs (the cell seeding density and culture medium change ratio) to satisfy two CQAs (the number of adhesion cells and ammonia concentration)18.

For the determination of DSs, traditional experiment-based approaches have been replaced with mathematical model-based methods19. Conventional DSs are based on the design of experiments to evaluate the effects of CPPs on CQAs, and their correlation can be statistically analyzed to determine DSs19. However, one drawback is the need for a comparatively high number of experiments19, which is critical for time-consuming and expensive processes, including MSC cultivation. Thus, supported by experiment-based investigations, model-based methods can enhance the exploration of DSs19. Specifically, from the viewpoint of process systems engineering (PSE), modeling is a strong tool for the determination of DSs in pharmaceutical processes, such as those for cultivating cells for cell therapy20. In particular, models can be used to determine DSs19 with stochastic techniques (e.g., Monte Carlo simulation) that consider system variability (e.g., probabilistic DS on the basis of the minimum acceptable risk21). Furthermore, the need for a time-dependent representation of DSs (e.g., dynamic DSs) was discussed on the basis of dynamic models involving ordinary differential equations (ODEs) to address the effects of CPPs on CQAs over time22. The state-of-the-art DS determination method for MSC cultivation specifies a dynamic and probabilistic DS, which accounts for both growth kinetics and variability in MSC cultivation18. However, the development of methods for DS validation is still in its infancy and is needed for industrial DS determination.

For MSC cultivation processes, a kinetic analysis of growth and metabolism to gain an understanding of the system was established prior to model development23. On the basis of these results, a set of ODEs was subsequently developed for cell growth, assuming Monod kinetics considering substrate limitation24 and metabolite and contact inhibition25. As initial steps of cultivation, cell adhesion and lag time were also integrated with ODEs18. Furthermore, spatial growth limitations due to the initial distribution of adhesion cells were addressed by incorporating phase contrast microscopy image data into ODEs26. Recently, this model was applied to MSC cultivation processes to find a feasible seeding density and harvesting time to satisfy the given number of adhesion cells and confluency level26, which can be used to assess DSs with this model and simulations. However, concerns remain about the reliability of DSs in MSC cultivation processes, as they have yet to be experimentally validated.

In this work, a model-based method is proposed to determine a DS via prediction intervals such that it can be experimentally validated for MSC cultivation processes. Two sets of cultivation experiments were conducted to apply the most recent kinetic model26; the first set of experimental data (Exp 1) were used to determine DSs via a published method18, whereas the second set of experimental data (Exp 2), which were obtained by three distinct operators, were used for DS validation. However, the calculated DS failed to be validated, with many conditions being incorrectly identified as part of the DS. To overcome this difficulty, we implemented the following four steps: (1) re-estimate the maximum specific growth rate to refine the model using a portion of the Exp 2 data; (2) simulate the upper and lower limits of the growth prediction using 95% prediction intervals of the kinetic model parameter, i.e., the maximum specific growth rate; (3) determine probabilistic DSs with different values of minimum acceptable risk while considering the upper and lower limits of the growth prediction; and (4) validate the obtained DS against the remaining Exp 2 data. The DS was validated with few false positive results, indicating robust conditions for the MSC cultivation process. The presented method can address intrinsic growth variability and thus enhance the applicability of models and the reliability of DSs for the design of industrial MSC cultivation processes.

Results

Overall approach for determining and validating the design space

The conventional DS determination method for MSC cultivation processes18 was applied with a prior kinetic model26 and the data from Exp 1 to determine DSs, as shown in the Supplementary Results (Fig. S1a–c). Here, the model26 is a set of ODEs used to simulate previously described CQAs (the number of adhesion cells, N, and confluency level, P)26 as a function of CPPs (the seeding density, Xseed, and harvesting time, th)26. Regarding the CQAs, N reflects self-renewal capacity, specifically, the growth rate, which was correlated with cell potency27. A high level of P represents cell properties, changing self-renewal capacity28 and biomarker expressions15. The DS was subsequently defined as sets of CPPs to meet CQAs with a probability equal to or greater than a user-specified minimum acceptable risk21, which was set as 90%. The following quality specifications were defined as the same as those in a previous work26:

N,P5.0×104NP<0.8

The resulting DS was evaluated with probabilities calculated from the Exp 2 data to ensure the specifications. Additionally, it was possible to classify experimental conditions, i.e., different combinations of Xseed and th, into four different categories by comparing the probabilistic DS with the Exp 2 data on the basis of metrics developed in prior work29, namely, CDS (correctly identified feasible condition), CDS¯ (correctly identified infeasible condition), IDS (incorrectly identified feasible condition), and IDS¯ (incorrectly identified infeasible condition). This validation failed with too many IDS conditions incorrectly identified as a part of the DS (Fig. S1d; see Supplementary Results and Fig. S2 for details).

To overcome the insufficient validation of the calculated DS, the conventional method18 was refined such that the DS could be experimentally validated (Fig. 1). Specifically, some of the Exp 2 data were used to re-estimate μm. Moreover, prediction intervals of μm were calculated to generate the lower and upper limits of growth predictions. Finally, the probability of both limits meeting the specifications was calculated to determine DSs, followed by DS validation using the remaining Exp 2 data. The total CPU time for the execution of the whole process in the proposed method was approximately 10 min.

Fig. 1. Proposed design space determination and validation workflow.

Fig. 1

The initial and pre-experimental data were used to determine a design space (DS). The validation experimental data were used to validate the DS with the four categories. The categories that were defined by the DS boundary where the predicted probability was 90% (solid circle) and the experimental results where the experimental probability was 90% (dashed circle). α: adhesion ratio; ε: seeding heterogeneity; μm: maximum specific growth rate; μmUP: upper bound of prediction interval of μm; μmLO: lower bound of prediction interval of μm; Npi=UP and Npi=LO: upper and lower limits of predicted number of adhesion cells, respectively; Ppi=UP and Ppi=LO: upper and lower limits of predicted confluency, respectively; Xm: maximum cell density; Xseed: seeding density; Xpi=UP and Xpi=LO: upper and lower limits of growth prediction, respectively; th: harvesting time; CDS: correctly identified feasible condition; CDS¯: correctly identified infeasible condition; IDS: incorrectly identified feasible condition; and IDS¯: incorrectly identified infeasible condition.

Re-estimation of the maximum specific growth rate and model validation

For DS determination, μm was re-estimated with part of the Exp 2 data. Exp 2 was conducted for nine days with seeding densities of 1500, 3000, and 4500 cells  cm−2 and was designed to closely mimic Exp 1 but with key differences, including the involvement of three distinct operators (Operators A, B, and C; Exps 2A, 2B, and 2C). Specifically, μm was re-estimated via the data from Exp 2A as a pre-experiment, whereas the data from Exp 2B and 2 C were reserved for validating the model (validation experiments). The fit to the number of adhesion cells measured at different time points for all the individual cultivations in the pre-experiment (i.e., Exp 2A; a total of 18 samples; 3 densities × 6 replicates) yielded mean and sample standard deviation values of μm of 2.76 × 10−2 h−1 and 1.46 × 10−3 h−1, respectively, on the basis of the least squares optimization method (Table S1), with the NRMSE being less than 10%, indicating a better fit to the pre-experimental data than that before the re-estimation (Fig. 2a). Moreover, the NRMSEs between the model predictions obtained using the re-estimated μm and the corresponding measurements in the validation experiment were less than 10% (Fig. 2b), which indicated that the model could be used for DS determination.

Fig. 2. Re-estimation of the maximum specific growth rate results.

Fig. 2

a Model fit to the mean of the experimental number of adhesion cells from Exp 2A for a given seeding density (dashed red lines) compared with the corresponding initial model prediction before re-estimation (black lines). The error bars show the means and standard deviations of the six samples. The normalized root mean square error for the model fit (NRMSE(fit)) and the initial model (NRMSE(initial)) are annotated on the plot. b Model validation using the experimental number of adhesion cells from Exps 2B and 2C for a given seeding density (orange lines). The error bars show the means and standard deviations of the 12 samples. The gray scatters represent the individual samples. The normalized root mean square error for the model validation (NRMSE(validation)) is annotated on the plot.

Prediction interval of the maximum specific growth rate and limits of growth prediction

To incorporate the variability of the re-estimated μm into a DS determination, two-sided 95% prediction intervals30 of μm were calculated. On the basis of the mean and sample standard deviation of the re-estimated μm, both the upper and lower bounds of the prediction interval of μm were set as follows:

μmUP=3.07×102h1
μmLO=2.44×102h1

The calculated μmUP and μmLO values were substituted into μm (Eq. (6)) to simulate the corresponding upper and lower limits of the model prediction, respectively. Here, the limits of the predicted number of adhesion cells were visualized with the corresponding measurements in the validation experiments (Exps 2B and 2C) (Fig. 3a). These limits indicated the possible growth variation over time to expand upon the average predicted curve (Figs. 2b and 3a). However, the upper and lower limits did not reflect the actual measurements at certain time points. In particular, the lower limits tended to exceed the measurements at earlier time points when there were large errors between the model predictions and the experimental data (Fig. 2b).

Fig. 3. Limits of the growth prediction results.

Fig. 3

a Dynamic simulation of the upper and lower limits with green and blue lines, respectively, for a given seeding density. The error bars show the means and standard deviations of the 12 samples in Exps 2B and 2C. The gray scatters represent the individual samples. b Dynamic and stochastic simulations of the upper and lower limits with light green and blue lines, respectively, for a given seeding density.

In addition to capturing the variability in μm, other sources of variation were accounted for by randomly sampling the model parameters on the basis of the Exp 1 and Exp 2 A data. Here, different levels of variation originating from MSC cultivation, as categorized in a prior work18, were incorporated, specifically, the seeding heterogeneity, ε (operation level), the adhesion ratio, α (cell level), and the maximum cell density, Xm (cell level) (Table S2). The resulting variations in the simulated limit were interpreted with underlying biological activities over time. In the cell adhesion phase (around Day 1), low Xseed values resulted in small variations in both the upper and lower limits because Xseed and α mainly affected the number of adhesion cells. In the subsequent growth phase, higher Xseed values yielded smaller variations in both limits because the cell density approached confluency earlier, which decreased the growth rate and then mitigated the variation (Fig. 3b). Here, 1000 iterations were conducted, with good convergence of the simulation results; specifically, the relative standard deviations of the mean of the final number of adhesion cells were less than 0.2% for all Xseed values, which indicated that 1000 iterations would be sufficient.

Determination and validation of the design space

To obtain a DS that can be experimentally validated, the simulated limits based on the prediction intervals of μm were used to calculate the probability of both limits meeting the quality specifications. Following the pre-experimental conditions, Xseed was set from 1500 to 4500 cells cm−2 with a numerical increment of 375 cells cm−2, whereas th was explored during Days 1–9 every 6 h, resulting in 297 combinations of Xseed and th. The resulting probabilistic DS was visualized as a set of feasible Xseed and th with a 2-dimensional contour map. The results suggested that a low Xseed was desirable at the cost of a long th (Fig. 4a). For example, at seeding densities of 1500, 3000, and 4500 cells cm−2, the cells needed to be cultivated for approximately 7.5–8, 6–7, and 5.25–6.25 days, respectively (Fig. 4a). In contrast, a high Xseed was considered desirable in terms of the number of design choices. Specifically, the feasible range of th was narrower at lower Xseed values (e.g., only a 0.5-day range for a seeding density of 1500 cells cm−2) than at higher Xseed values (e.g., a 1-day range for seeding densities of both 3000 and 4500  cells cm–2) (Fig. 4a). This result was supported by the data shown in Fig. 4a, where the gap between limits was larger in the lower Xseed experiment, indicating higher uncertainty and resulting in a decrease in the calculated probability and consequently a narrower range of feasible th.

Fig. 4. Probabilistic design space and validation results.

Fig. 4

a Design space determination. The contour map shows the predicted probability as a function of seeding density and harvesting time with a design space (DS) boundary where the probability is 90% (black lines). b Design space validation. The black lines represent the DS with the resulting categories out of CDS, correctly identified feasible condition (green dots); IDS, incorrectly identified feasible condition (red); CDS¯, correctly identified infeasible condition (blue); and IDS¯, incorrectly identified infeasible condition (yellow).

The DS validation was conducted for conditions both inside and outside the DS. Specifically, we evaluated 99 experimental conditions with sets of Xseed values of 1500, 3000, and 4500 cells cm−2 and th values over Days 1–9 every 6 h (a total of 33 measurement points). For each Xseed and th, a total of 12 samples were investigated by two operators (Exps 2B and 2C; each analyzing 6 samples) to calculate the probability of the experimental data satisfying the specifications. The probability was subsequently used to categorize the 99 conditions into the four categories defined in Fig. 1. The resulting categories indicated that twelve conditions were included in the DS (those classified as CDS and IDS), among which 11 conditions were confirmed as feasible in the validation experiment (CDS) (Fig. 4b). This result yielded an R1 (the ratio of conditions included in the DS that were feasible to the total number of conditions in the DS) of 0.917 (Eq. (21)). The conditions classified as IDS resulted in many adhesion cells in the simulation; specifically, the lower limit of predictions led to the overestimation of the number of adhesion cells that could still meet the quality specification. The resulting high R1 value suggested that the DS could serve as a reliable condition for MSC cultivation.

Additionally, other ratios were investigated to evaluate the validation results. From an experimental perspective, 29 conditions were identified as feasible (CDS and IDS¯), among which 11 conditions were included in the DS (CDS) (Fig. 4b). From these categories, R2 (the ratio of the feasible conditions correctly included in the DS to the total number of feasible conditions) was 0.379 (Eq. (22)), potentially because of the conservative prediction of the confluency level. Specifically, the upper limit of predictions indicated that the confluency level did not meet the specification, but the measured confluency did. In contrast, 70 conditions were identified as infeasible in the experiment (CDS¯ and IDS¯), among which 69 were correctly identified as being outside the DS (CDS¯) (Fig. 4b). From these categories, R3 (the ratio of the number of infeasible conditions correctly discovered by the DS to the total number of infeasible conditions) was 0.986 (Eq. (23)). These resulting low R2 and high R3 values suggested that more than half of the conditions required to meet the specifications were not identified, but most of the infeasible conditions were correctly excluded from the DS, which would be beneficial to potential producers, users, and consumers (e.g., patients receiving MSC therapy).

Effects of prediction intervals on the determination and validation of design spaces

To investigate the effects of the prediction interval of μm on the determination and validation of the new DS, a reference DS was determined following the re-estimation of μm but without calculating the prediction interval of μm. The reference DS included more conditions than those generated with consideration of limits of growth predictions (Fig. 5a, c). However, the reference DS resulted in a lower R1 than the new DS (Table S3); specifically, the new DS achieved a reduction in the number of IDS conditions (Fig. 5b, d). Simultaneously, this reduction yielded a higher R3 but a lower R2 because of the tradeoff between the IDS and IDS¯ conditions; namely, the IDS¯ conditions increased (Table S3). This result confirmed that few conditions were incorrectly identified as part of the DS, suggesting that the prediction interval of μm enabled the DS to represent a conservative estimate of the reliable conditions for MSC cultivation. This reduction in the number of IDS conditions would be beneficial for MSC manufacturers because the cultivation conditions can be safely selected within the DS, ensuring that product specifications are met.

Fig. 5. Design space determination and validation results without/with prediction interval calculation.

Fig. 5

a Design space without prediction interval calculation. b Validation of the design space without the prediction interval. c Design space with prediction interval calculation. d Validation of the design space with the prediction interval. Here, the contour map shows the predicted probability as a function of the seeding density and harvesting time. The black lines show the design space with the resulting categories out of CDS, correctly identified feasible condition (green dots); IDS, incorrectly identified feasible condition (red); CDS¯, correctly identified infeasible condition (blue); and IDS¯, incorrectly identified infeasible condition (yellow).

Determination and validation of the design space with different pre- and validation experiments

To further investigate the applicability and reliability of the new DS, the determination and validation of DSs were extended to different sets of pre- and validation experiments subject to different minimum acceptable risks, π. Specifically, one experiment from Exp 2 (e.g., Exp 2B) was used for the pre-experiment, whereas the remaining experimental data were used for the validation experiments (e.g., Exps 2C and 2A). Following the re-estimation of μm via pre-experimental data, model validation, and prediction interval calculation (Fig. S3), a DS was determined and then validated for π values of 50, 70, and 90%. The resulting DSs indicated that the area covered by the DS narrowed as π increased (Fig. S4). This trend was observed for all the pre-experimental data (Fig. S4a–c). Some combinations of π and pre-experiments, such as those shown in Fig. S4c, provided no DS (i.e., no white area) because all the calculated probabilities were lower than π. This occurred because there was a large sample standard deviation for μm in the pre-experimental data (i.e., Exp 2C) that expanded the prediction interval of μm and, correspondingly, the range of the limits of growth prediction. Regardless of the chosen π and pre-experimental conditions, these DSs included only a small number of IDS conditions (Fig. 6), resulting in high R1 and R3 values at the cost of a lower R2 (Table S4). This result suggested that pre-experiments with little variation in the data, such as Exp 2A and 2B, are preferred if the required π is relatively high; this finding is relevant for industrial MSC cultivation process design. Together, these results suggest that the DS could be experimentally validated, ultimately providing reliable conditions for the design of the MSC cultivation process.

Fig. 6. Design space validation results with different pre-experiments.

Fig. 6

The design spaces were determined via preliminary results and then validated with validation experimental results for a given minimum acceptable risk, π. The black lines represent the DS with the resulting categories out of CDS, correctly identified feasible condition (green dots); IDS, incorrectly identified feasible condition (red); CDS¯, correctly identified infeasible condition (blue); and IDS¯, incorrectly identified infeasible condition (yellow). a Exp 2A and Exps 2B and 2C were used for the pre-experiment and validation experiments, respectively. b Exp 2B and Exps 2C and 2A were used for the pre-experiment and validation experiments, respectively. c Exp 2C and Exps 2A and 2B were used for the pre-experiment and validation experiments, respectively.

Discussion

A model-based method to determine a probabilistic DS for MSC cultivation processes was presented and validated with experimental data. The originality of this work lies in the creation of a model-based method that combines experimental and numerical procedures to guide the determination and validation of DSs (Fig. 1). The method can provide more clarity to the design of cell cultivation processes, overcoming the inconsistency in model performance due to experimental variabilities such as differences in cell source, operator, and other factors. Such reproducibility issues commonly encountered in cell cultivation3133 could be overcome by applying this method. In this method, the value of the maximum growth rate parameter μm is crucial; hence, there were additional steps for re-estimating μm on the basis of a pre-experiment to increase the model accuracy and, ultimately, its applicability to different MSC cultivation conditions. The re-estimation of μm addressed the discrepancies and variabilities that arose from experiments. For example, the MSCs cultivated in Exps 1 and 2A–2C were seeded from the same lot, but the apparent growth rates measured in Exps 2A–2C were much slower than those in Exp 1. To incorporate such growth variability within a given lot, one set of experimental data of interest (i.e., Exp 2A) was used to re-estimate μm, which allowed model validation with the data from Exp 2B and 2C to be successful. This procedure was also used with different permutations of data in the pre-experiment (e.g., Exp 2C) and validation experiments (e.g., Exps 2A and 2B), thus accounting for operator variability; specifically, the relevant parameter re-estimation and model validation resulted in sufficiently small NRMSEs (Fig. S3). These results suggest that the pre-experiment and the re-estimation of μm made the model for DSs more generalizable across cell sources within a single lot. Moreover, the results also addressed inconsistency in cultivation results due to operator variability, which can be of industrial relevance toward commercial MSC manufacturing.

Furthermore, the implementation of a prediction interval for μm supported the discernment of a feasible operation region in the DS while respecting a range of minimum acceptable risk (π of 50–90%). The use of the prediction interval of μm is beneficial for incorporating growth variations among cell populations from the same source into process design. For example, upper and lower limits of growth predictions can be generated to incorporate the likely variation on the basis of pre-experimental data into the DS, such that only reliable cultivation conditions are included. This approach could be extended to other pharmaceutical cell cultivation processes that involve growth variations among cell populations from the same source. With increased volume of experimental data, the prediction intervals of μm would converge, which could mitigate statistical uncertainty in simulations to establish more reliable DSs for cultivation processes.

The impact of the sample size on the predictive capacities of the model was evaluated (see Supplementary Results for details). The results of model validation were more susceptible to the sample size than those of model fitting, indicating that a minimum acceptable size was twelve for a given accuracy criterion of 10% (Fig. S5). Furthermore, the impact of these sizes on the DS validation results (Fig. S6) indicated that a total of 18 samples were necessary to yield an R1 value (i.e., precision) of 90% (Tables S4 and S5). These results suggest that pre-experiments should be designed aiming at the validation of DSs rather than the model itself, which would not only ensure the accuracy of the model but also enhance the reliability of the DSs.

The present model would be useful for various scenes in research, development, and manufacturing of MSCs. In research, for example, the model can be used for uncertainty and sensitivity analysis of experimental parameters (e.g., seeding heterogeneity) of cell cultivation. For manufacturing, the model-based DS could serve as a basis for quantitative decision-making to fulfill a specified product requirement (e.g., dose) subject to timeline constraints (e.g., scheduling).

Given the simplicity of the model and the experiments with a single lot of MSCs, the results presented are concerned with specific cell sources and experimental setups. Cell phenotype can deviate along cultivation in many ways including confluency15. To mitigate such deviations, the daily replacement of half of the medium was conducted in the experiment, and thus, it was assumed in the model that the nutrients (e.g., glucose) and metabolites (e.g., lactate) exhibited consistent effects on growth kinetics. Moreover, MSC cultivation is characterized by cell division, contact inhibition15,25, initial cell spatial distribution26, cell migration34,35, morphology36, and mechanotransduction37. Among these specificities, the model focuses on cell division (i.e., number-based description) with the aim of considering the effects of the initial spatial distribution on the growth. Our prior model26 enabled the incorporation of the spatial growth limitation due to seeding heterogeneity (see Fig. 5 in ref. 26), which was specific to MSC cultivation, and this was inherited by the present model (see also Fig. 2). The model could serve as a basis for capturing further specificities of MSC cultivation.

The developed procedure (Fig. 1) can be applied to various design cases of MSC cultivation by necessary adjustment with different levels. The common concept here is that the initial experiment (e.g., Exp 1) establishes a baseline of a model for a given lot and experimental setup, while pre-experiments (e.g., Exp 2) aim to quantify and incorporate variability within the lot and setup into the model prediction. The following three scenarios could provide practical guidance for the use of this procedure.

  • For MSCs from different batches within the same lot and cultivation condition as this work, only pre-experiments are performed to incorporate growth variability within the lot.

  • For MSCs from different lots (e.g., tissue38, donor25,39) under the same condition as this work, an initial experiment is first conducted for the given lot to establish a baseline for the model under controlled culture conditions. If the model fails to demonstrate the growth kinetics in the initial experiment, model adjustments are needed (e.g., introduction of new parameters). Subsequently, pre-experiments are performed to incorporate growth variability within the lot, while investigating broader conditions (e.g., seeding density, harvesting time), including those relevant to the manufacturing settings.

  • Regardless of the source of MSCs, if either the medium composition or the cultivation scale/configuration differs from that employed in this work, a new set of models should be developed. The set of ODEs can be renewed to predict mechanistic cell behavior more rigorously, by adopting, among others, time-dependent metabolism subject to a medium change18 and growth kinetics on microcarriers using a bioreactor40. An initial experiment is then conducted for the given lot and experimental setup (i.e., medium composition, scale/configuration) to establish a baseline for the model, followed by pre-experiments incorporating growth variability within the lot under the setup.

As a potential limitation of this work, only quality indicators that can be modeled were employed as the CQAs in this method. Consequently, non-modeled CQAs that correlate with the potency of MSCs should be addressed with further analyses or assays toward clinical applications. For example, cell aging16 has not been included in the quality specifications used to determine a DS. Cell aging is negligible in the absence of subcultures, as the accumulated number of cell divisions in a single cultivation experiment was smaller than that observed when the aging of bone marrow-derived MSCs occurred16. In future work, more experimental results could be explored to enhance the understanding of additional quality indicators and accelerate further computational investigations, improving the robustness of the design of MSC cultivation processes.

Methods

Cell culture

Bone marrow-derived MSCs (Lonza Japan, Ltd., Tokyo, Japan; lot number 19TL281098) were thawed, rinsed with MSCGM (Lonza Japan, Ltd., Tokyo, Japan; lot number 0001099016), counted, and then directly seeded in a 6-well plate (353046; Corning Incorporated, Corning, NY, USA). To match the image-analyzed number of cells with the total number of seeded cells, a restricted culture area was created in each well of the 6-well plates (353046, FALCON, NY, USA) using polydimethylsiloxane (PDMS) as described previously26. The restricted culture area (17 × 17 mm) was designed to be slightly larger than the total tiling image size (15.3 × 15.3 mm). Exp 1 was designed to collect initial data under controlled conditions to establish a baseline for the kinetic model. MSCs were seeded at a density of 2.0 × 103 cells cm–2 (n= 6) in the restricted area. All operations were conducted by a single operator. Exp 2 aimed to validate the model under broader and more variable conditions by including three operators (Exp 2A, 2B, 2C) using a different batch of MSCs from the same lot as Exp 1. MSCs were seeded at densities of 1.5 × 103, 3.0 × 103, and 4.5 × 103 cells cm–2 (n= 6 for each condition) to explore a wider range of seeding conditions. After 1 mL of cells was seeded, the plate was incubated for 1 h to allow cell adhesion. Then, an additional 1 mL of medium was added to bring the total culture volume to 2 mL, ensuring that the liquid surface height was greater than the PDMS height to eliminate the meniscus effect. In Exp 1, all operations were performed by a single operator, and the culture period was 8 days, with 50% of the culture medium replaced every 48 h. In Exp 2, operations were carried out by three different operators (Exp 2A, 2B, and 2C). The cells were cultured for 9 days, and 50% of the culture medium was replaced every 24 h. The culture period was designed to cover not only the early sparse status of the cells but also the confluence status to cover the total culture period to fit the simulation growth curve.

Image acquisition and processing

Phase contrast microscopy images were automatically acquired every 6 h via BioStation CT (Nikon Corporation, Tokyo, Japan) at 4× magnification (8 × 8 tiling per well, 15.3 × 15.3 mm, 1000 pixels/image). Imaging started 1 h after seeding and continued for 8 to 9 days. Since the tiling image was designed to cover the total cell culture area, we used image processing to count the growth of total seeded cells. Image processing for segmentation and cell counting per image was carried out with the processing pipeline described previously26. Image processing and data processing were performed via original codes via Python 3.9.13 with the packages NumPy 1.20.0 and OpenCV 4.4.0.

Parameter value calculation from experimental data

For each cultivation sample, the adhesion ratio, seeding heterogeneity, and maximum cell density were calculated via the number of adhesion cells counted in the images. Here, the adhesion ratio, α, was defined as the ratio of the sum of the number of adhesion cells counted from all the images on Day 1 to the number of seeded cells; the seeding heterogeneity, ε, was the population standard deviation of the normalized number of adhesion cells counted from each image on Day 126; and the maximum cell density, Xm, was calculated on the basis of the maximum number of adhesion cells counted from each image from Day 1 to the end of cultivation as follows:

α=i64NiimgSXseed 1
ε=164i64Niimgj64Njimg1642 2
Xm=64maxNimgS 3

where Nimg is the number of adhesion cells counted from each image, S is the surface area of the 15.3 mm diameter space, Xseed is the seeding density (see also Table 1), and max is the function that obtains the maximum value.

Table 1.

Description of symbols, Greek letters, and acronyms

Symbols
A Quality specification
CDS Correctly identified feasible condition
CDS¯ Correctly identified infeasible condition
f Kinetic model function
h % Probability based on prediction
hexp % Probability based on experiment
I Indicator function
IDS Incorrectly identified feasible condition
IDS¯ Incorrectly identified infeasible condition
Ks Spatial limitation constant
Ln Parameter combination
M Number of model iterations
nnsample Number of samples
nmeasure Number of measurements
nCDS Number of correctly identified feasible conditions
nCDS¯ Number of correctly identified infeasible conditions
nIDS Number of incorrectly identified feasible conditions
nIDS¯ Number of incorrectly identified infeasible conditions
N Number of adhesion cells
Nexp Number of experimentally measured adhesion cells
Nimg Number of adhesion cells counted in an image
Npi Limits of the predicted number of adhesion cells
Npi=UP, Npi=LO Upper and lower limits of the predicted number of adhesion cells
pi Prediction interval
P Confluency level
Pexp Experimentally measured confluency level
Ppi Limits of the predicted confluency level
Ppi=UP, Ppi=LO Upper and lower limits of the predicted confluency level
R1 Ratio of conditions included in the DS that are feasible to the total number of conditions in the DS
R2 Ratio of the number of feasible conditions correctly included in the DS to the total number of feasible conditions
R3 Ratio of the number of infeasible conditions correctly included in the DS to the total number of infeasible conditions
s Sample standard deviation
S cm2 Surface area
t h Cultivation time
th day Harvesting time
tp,r p quantile of Student’s t distribution with r degrees of freedom
X cells  cm−2 Adhesion cell density
X0 cells  cm−2 Cell density on Day 1
Xm cells  cm−2 Maximum cell density
Xseed cells  cm−2 Seeding cell density
Xpi Limits of the predicted adhesion cell density
Xpi=UP, Xpi=LO cells  cm−2 Upper and lower limits of the predicted adhesion cell density
x Design variable
ypi Limits of the model predictions
ypi=UP, ypi=LO Upper and lower limits of the model predictions
Greek letters
α Adhesion ratio
ε Seeding heterogeneity
θ Parameter matrix
μ h−1 Specific growth rate
μm h−1 Maximum specific growth rate
μmUP, μmLO h−1 Upper and lower bounds of the prediction interval of the maximum specific growth rate
π % Minimum acceptable risk
Acronyms
CMA Critical material attribute
CPP Critical process parameter
CQA Critical quality attribute
DS Design space
Exp 1 Initial experiment
Exp 2A Second experiment by operator A
Exp 2B Second experiment by operator B
Exp 2C Second experiment by operator C
LO Lower bound of a prediction interval
MSC Mesenchymal stem cell
NRMSE Normalized root mean square error
NRMSE(fit) NRMSE for the model fit
NRMSE(initial) NRMSE for the initial model prediction
NRMSE(validation) NRMSE for the model validation
ODE Ordinary differential equation
PDMS Polydimethylsiloxane
PSE Process systems engineering
QbD Quality by design
RSS Residual sum of squares
UP Upper bound of a prediction interval

Model formulation

The previous kinetic model of MSC cultivation processes with a set of ordinary differential equations (ODEs)26 was applied in this work. Specifically, the following three equations were formulated to describe time-dependent changes in adhesion cell density on the basis of the specific growth rate while considering spatial limitation and contact inhibition as follows26:

dXdt=μX 4
X0=αXseed 5
μ=μm1εKs1XXm 6

where X is the adhesion cell density at a given cultivation time, t; X0 is the cell density on Day 1; α is the adhesion ratio; ε is the seeding heterogeneity; μ is the specific growth rate; μm is the maximum specific growth rate; and Ks is the spatial limitation constant (see also Table 1). The scipy.integrate.solve_ivp solver was used with its default parameters for solving the ODEs in Python 3.9.13 via an Intel Xeon Gold 6142 CPU @ 2.60 GHz with 128 GB of RAM.

Estimation of the maximum specific growth rate

The experimental data were used to estimate the value of μm in the kinetic models. The value of Ks was 24.7 [–] from the literature26, whereas the other parameter values in the equations (i.e., α, ε, and Xm) were set as the means of the experimental data (Table S2). To use the least squares method, the residual sum of squares (RSS)41 was calculated for each sample as follows:

RSSi=j=1nmeasureNi,jexpNi,j2 7

where RRSi is the calculated RSS for a given sample; Ni,jexp is the measured number of adhesion cells; Ni,j is the predicted number of adhesion cells; and nmeasure is the number of measurements (see also Table 1). The RSS was subsequently minimized to obtain the value of μm for each sample, which yielded their mean value as the estimate of μm. This minimization was performed with the scipy.optimize.minimize function by setting its solver as Nelder‒Mead, its maximum number of iterations as 5000, and its other parameters as defaults in Python 3.9.13.

To evaluate the errors between the experimental data and the model prediction, the NRMSE41 was calculated for each seeding density as follows:

NRMSEk=1nsamplenmeasurei=1nsamplej=1nmeasureNi,jexpNi,j2maxNkexpminNkexp×100% 8

where NRMSEk is the calculated NRMSE for a given seeding density; nsample is the number of samples (see also Table 1); and maxNkexp and minNkexp are the maximum and minimum values of the measured number of adhesion cells for a given seeding density, respectively.

Model validation

The model was validated by confirming an NRMSE between the model prediction and the remaining experimental data for each seeding density of less than a prior threshold of 10%18. With respect to the model inputs, the parameter values of α, ε, and Xm were the same as those used for the μm parameter estimation. In addition, the estimated μm was used as a model input.

Prediction interval calculation

Two-sided 95% prediction intervals30 of the estimated μm were calculated as follows:

μmUP=μm+t0.975,n1s1+1n 9
μmLO=μmt0.975,n1s1+1n 10

where μmUP and μmLO are the upper and lower bounds of the prediction interval of μm, respectively; t(p,r) is the p quantile of the Student’s t distribution with r degrees of freedom; s is the sample standard deviation of μm; and n is the number of samples (see also Table 1). Here, tp,r was calculated with the default t test function implemented in the scipy library in Python 3.9.13.

Dynamic and stochastic simulation

Given a set seeding density and harvesting time, time-dependent changes in cell growth were simulated until day 9 at the end of cultivation (i.e., dynamic simulation). Variations in the growth kinetics were predicted by determining the upper and lower limits; specifically, μmUP and μmLO were substituted into μm in Eq. (6), respectively. Additionally, to account for the effects of other sources of variation, such as operation variability, on time-dependent changes in cell density and confluency, the input parameters (i.e., α, ε, and Xm) were randomly selected from the individual experimental measurements (Table S2) and substituted into the kinetic model. This dynamic simulation was repeated with random sampling of the parameters (i.e., dynamic and stochastic simulation) until the outputs converged; specifically, relative standard deviations of the mean of the final number of adhesion cells were evaluated at the end of the iteration. Here, the sampling was performed with the default numpy.random.choice function implemented in Python 3.9.13.

Design space determination

The probabilistic DS was determined on the basis of the dynamic and stochastic simulation results to ensure the following quality specifications for the number of adhesion cells and confluency level, which were the same as those in prior work26.

A=N,P5.0×104NP<0.8 11

where A is the set of quality specifications; N is the number of adhesion cells; and P is the confluency level (see also Table 1). Here, a previously described algorithm18,21 was used to calculate the probability to define a DS as follows:

hCPP=1Mi=1MIyiA×100% 12

where h is the calculated probability; CPP is a set of CPPs; I is an indicator function, which takes a value of 1 if all conditions are satisfied and 0 if at least one condition is not satisfied; M is the number of model iterations for a given design variable; and y is the model prediction (see also Table 1).

In this work, the abovementioned algorithm was extended with a probability calculation using the limits of growth predictions as follows:

DS=x,tLnhx,tπ 13

s.t.

hx,t=1Mi=1MIyipi=UPAyipi=LOA×100% 14

where x,t is a set of seeding densities and harvesting times among the parameter combinations, Ln; π is a user-specified minimum acceptable risk; and ypi=UP and ypi=LO are the upper and lower limits of the model predictions, respectively (see also Table 1). Here, both limits contained the predicted outputs (i.e., number of adhesion cells, confluency level) on the basis of the prediction interval of μm; specifically, the outputs were calculated with the adhesion cell density, which was a function of seeding density and harvesting time as follows:

ypi=Npi,Ppi 15
Npi=SXpi 16
Ppi=XpiXm 17
Xpi=fx,t,μmUP,θ,pi=UPfx,t,μmLO,θ,pi=LO 18

where f is the kinetic model; Xpi represents the limits of the predicted adhesion cell density; Npi represents the limits of the predicted number of cells; Ppi represents the limits of the predicted confluency level; and θ represents an M× 3 matrix containing the values of three input parameters (i.e., α, ε, and Xm) (see also Table 1).

Design space validation

The conditions proposed on the basis of the DS results were experimentally validated to confirm whether the actual cultivation results met the specifications. The measurements in the validation experiment were used to calculate this probability, hexp.

hexp=1ni=1nINiexpAPiexpA×100% 19

where n is the number of samples in the validation experiment for a given condition; Nexp is the measured number of adhesion cells; and Pexp is the confluency estimated from the measurements (see also Table 1).

h and hexp were analyzed to categorize all the investigated cultivation conditions (i.e., sets of seeding density and harvesting time) into one of four categories as follows:

  • CDS: correctly identified feasible condition, in which both h and hexp are equal to or greater than π.

  • CDS¯: correctly identified infeasible condition, in which both h and hexp are less than π.

  • IDS: incorrectly identified feasible condition, in which h is equal to or greater than π but hexp is less than π.

  • IDS¯: incorrectly identified infeasible condition, in which h is less than π but hexp is equal to or greater than π.

In addition to these definitions, the following three metrics were defined to evaluate the DS.

  • R1: the ratio of the number of conditions included in the DS that were feasible in the validation experiment to the total number of conditions in the DS.

  • R2: the ratio of the number of feasible conditions in the validation experiment that were correctly included in the DS to the total number of feasible conditions.

  • R3: the ratio of the number of infeasible conditions in the validation experiment that were correctly included in the DS to the total number of infeasible conditions.

R1=nCDSnCDS+nIDS 21
R2=nCDSnCDS+nIDS¯ 22
R3=nCDS¯nCDS¯+nIDS 23

where nCDS, nCDS¯, nIDS, and nIDS¯ are the numbers of conditions classified as CDS, CDS¯, IDS, or IDS¯, respectively (see also Table 1). If the values of R1, R2, and R3 are all close to 1, the model-based DS can be considered to provide robust cultivation conditions. In particular, R1 represents how conservatively the DS proposes feasible conditions, which suggests that a high R1 value would enable cell manufacturers to safely select feasible conditions from the DS.

Statistics and reproducibility

All available data from the cultivation experiments were used, and no statistical method was employed to determine the sample size. No data were excluded from the analysis. The cultivation experiment with each condition was replicated six times independently. Three sets of samples were allocated with every permutation. The authors performed every permutation and, therefore, were not blinded to the sample allocation.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Supplementary information

Supplementary Data 1 (25.1KB, xlsx)
Supplementary Data 2 (820.4KB, xlsx)
Supplementary Data 3 (165.6MB, xlsx)
Supplementary Data 4 (25KB, xlsx)
Supplementary Data 5 (3.4MB, xlsx)
42003_2025_8063_MOESM7_ESM.pdf (55.6KB, pdf)

Description of Additional Supplementary Materials

Reporting summary (1.3MB, pdf)

Acknowledgements

This research was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP20be0704001. K.H. is grateful for the financial support of Grant-in-Aid for JSPS Fellows (Grant Number JP23KJ0375).

Author contributions

K.H. Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Data curation, Original manuscript draft, Manuscript review & editing, Visualization. Y.H. Conceptualization, Methodology, Validation, Formal analysis, Original manuscript draft, Manuscript review & editing, Visualization. I.A.U. Conceptualization, Methodology, Validation, Formal analysis, Visualization. M.R.G. Manuscript review & editing. K.T. Conceptualization, Investigation, Data curation, Original manuscript draft, Manuscript review & editing. Y.T. Conceptualization, Software, Validation, Investigation, Data curation R.K. Conceptualization, Manuscript review & editing, Resources, Supervision, Project administration, Funding acquisition. M.K. Conceptualization, Resources, Supervision, Project administration, Funding acquisition. H.S. Conceptualization, Methodology, Manuscript review & editing, Resources, Visualization, Supervision, Project administration, Funding acquisition.

Peer review

Peer review information

Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Dr Eirini Trompouki and Dr Ophelia Bu.

Data availability

All data supporting the findings of this study are available within the article and Supplementary Information. The raw data from the experiments and the numerical source data are also available from Supplementary Data 1 and Supplementary Data 25, respectively.

Code availability

The code used in this study can be obtained from https://github.com/UTokyoPSE/Hirono_etal_DSValidation.git.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s42003-025-08063-2.

References

  • 1.Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv.6, eaba6884 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bydon, M. et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial. Nat. Commun.15, 2201 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat. Biomed. Eng.10.1038/s41551-024-01195-6 (2024). [DOI] [PMC free article] [PubMed]
  • 4.Aliakbari, F. et al. The impact of hUC MSC-derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity. Sci. Adv.10, eadl3406 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology142, 46–54 (2012). [DOI] [PubMed] [Google Scholar]
  • 6.Lipsitz, Y. Y., Timmins, N. E. & Zandstra, P. W. Quality cell therapy manufacturing by design. Nat. Biotechnol.34, 393–400 (2016). [DOI] [PubMed] [Google Scholar]
  • 7.Ministry of Health, Labour and Welfare. Report on the Deliberation Results. https://www.pmda.go.jp/files/000246420.pdf (2021).
  • 8.Samsonraj, R. M. et al. Establishing criteria for human mesenchymal stem cell potency. Stem Cells33, 1878–1891 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy8, 315–317 (2006). [DOI] [PubMed] [Google Scholar]
  • 10.Serra, M., Cunha, B., Peixoto, C., Gomes-Alves, P. & Alves, P. M. Advancing manufacture of human mesenchymal stem cells therapies: technological challenges in cell bioprocessing and characterization. Curr. Opin. Chem. Eng.22, 226–235 (2018). [Google Scholar]
  • 11.Grau-Vorster, M. et al. Compliance with good manufacturing practice in the assessment of immunomodulation potential of clinical grade multipotent mesenchymal stromal cells derived from Wharton’s Jelly. Cells8, 484 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yang, Y.-H. K., Ogando, C. R., Wang See, C., Chang, T.-Y. & Barabino, G. A. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res. Ther.9, 131 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cunningham, C. J., Redondo-Castro, E. & Allan, S. M. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J. Cereb. Blood Flow. Metab.38, 1276–1292 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bruder, S. P., Jaiswal, N. & Haynesworth, S. E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J. Cell. Biochem.64, 278–294 (1997). [DOI] [PubMed] [Google Scholar]
  • 15.Ren, J. et al. Human bone marrow stromal cell confluence: effects on cell characteristics and methods of assessment. Cytotherapy17, 897–911 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wagner, W. et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE3, e2213 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.ICH. Q8(R2) Pharmaceutical development. https://vnras.com/wp-content/uploads/2017/05/Q8R2_PHARMACEUTICAL-DEVELOPMENT.pdf (2009).
  • 18.Hirono, K. et al. A dynamic and probabilistic design space determination method for mesenchymal stem cell cultivation processes. Ind. Eng. Chem. Res.61, 7009–7019 (2022). [Google Scholar]
  • 19.Destro, F. & Barolo, M. A review on the modernization of pharmaceutical development and manufacturing—trends, perspectives, and the role of mathematical modeling. Int. J. Pharm.620, 121715 (2022). [DOI] [PubMed] [Google Scholar]
  • 20.Gaddem, M. R. et al. Roles of mechanistic, data-driven, and hybrid modeling approaches for pharmaceutical process design and operation. Curr. Opin. Chem. Eng.44, 101019 (2024). [Google Scholar]
  • 21.García-Muñoz, S., Luciani, C. V., Vaidyaraman, S. & Seibert, K. D. Definition of design spaces using mechanistic models and geometric projections of probability maps. Org. Process Res. Dev.19, 1012–1023 (2015). [Google Scholar]
  • 22.von Stosch, M. et al. Working within the design space: Do our static process characterization methods suffice?. Pharmaceutics12, 562 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Schop, D. et al. Growth, metabolism, and growth inhibitors of mesenchymal stem cells. Tissue Eng. Part A15, 1877–1886 (2009). [DOI] [PubMed] [Google Scholar]
  • 24.Higuera, G. et al. Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem cells using a mathematical model. Tissue Eng. Part A15, 2653–2663 (2009). [DOI] [PubMed] [Google Scholar]
  • 25.Jossen, V. et al. An approach towards a GMP compliant in-vitro expansion of human adipose stem cells for autologous therapies. Bioengineering7, 77–99 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hirono, K. et al. Image-based hybrid model incorporating initial spatial distribution for mesenchymal stem cell cultivation process design. AIChE J.70, e18452 (2024). [Google Scholar]
  • 27.Deskins, D. L. et al. Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection. Stem Cells Transl. Med.2, 151–158 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wolfe, M., Pochampally, R., Swaney, W. & Reger, R. L. Isolation and culture of bone marrow-derived human multipotent stromal cells (hMSCs). Methods Mol. Biol.449, 3–25 (2008). [DOI] [PubMed] [Google Scholar]
  • 29.Wang, Z. & Ierapetritou, M. A novel feasibility analysis method for black-box processes using a radial basis function adaptive sampling approach. AIChE J.63, 532–550 (2017). [Google Scholar]
  • 30.William, Q. M. et al. Escobar. Statistical Intervals: A Guide for Practitioners and Researchers (Wiley & Sons, 2017).
  • 31.Freedman, L. P. et al. Reproducibility: changing the policies and culture of cell line authentication. Nat. Methods12, 493–497 (2015). [DOI] [PubMed] [Google Scholar]
  • 32.Reynolds, P. M. et al. Controlling fluid flow to improve cell seeding uniformity. PLoS One13, e0207211 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hirsch, C. & Schildknecht, S. In vitro research reproducibility: keeping up high standards. Front. Pharmacol.10, 1484 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cholewa, D. et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transpl.20, 1409–1422 (2011). [DOI] [PubMed] [Google Scholar]
  • 35.Maijenburg, M. W., van der Schoot, C. E. & Voermans, C. Mesenchymal stromal cell migration: possibilities to improve cellular therapy. Stem Cells Dev.21, 19–29 (2012). [DOI] [PubMed] [Google Scholar]
  • 36.Matsuoka, F. et al. Morphology-based prediction of osteogenic differentiation potential of human mesenchymal stem cells. PLoS ONE8, e55082 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.McMurray, R. J., Dalby, M. J. & Tsimbouri, P. M. Using biomaterials to study stem cell mechanotransduction, growth and differentiation. J. Tissue Eng. Regen. Med.9, 528–539 (2015). [DOI] [PubMed] [Google Scholar]
  • 38.Kern, S., Eichler, H., Stoeve, J., Klüter, H. & Bieback, K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells24, 1294–1301 (2006). [DOI] [PubMed] [Google Scholar]
  • 39.Picken, A. et al. A Monte Carlo framework for managing biological variability in manufacture of autologous cell therapy from mesenchymal stromal cells therapies. Cytotherapy22, 227–238 (2020). [DOI] [PubMed] [Google Scholar]
  • 40.Jossen, V., Eibl, R., Kraume, M. & Eibl, D. Growth behavior of human adipose tissue-derived stromal/stem cells at small scale: numerical and experimental investigations. Bioengineering5, 106 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Daume, S., Kofler, S., Kager, J., Kroll, P. & Herwig, C. Generic workflow for the setup of mechanistic process models. in Animal Cell Biotechnology: Methods and Protocols, Vol. 2095 (ed. Pörtner, R.) 189–211 (Springer US, 2020). [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Data 1 (25.1KB, xlsx)
Supplementary Data 2 (820.4KB, xlsx)
Supplementary Data 3 (165.6MB, xlsx)
Supplementary Data 4 (25KB, xlsx)
Supplementary Data 5 (3.4MB, xlsx)
42003_2025_8063_MOESM7_ESM.pdf (55.6KB, pdf)

Description of Additional Supplementary Materials

Reporting summary (1.3MB, pdf)

Data Availability Statement

All data supporting the findings of this study are available within the article and Supplementary Information. The raw data from the experiments and the numerical source data are also available from Supplementary Data 1 and Supplementary Data 25, respectively.

The code used in this study can be obtained from https://github.com/UTokyoPSE/Hirono_etal_DSValidation.git.


Articles from Communications Biology are provided here courtesy of Nature Publishing Group

RESOURCES